



## Integrated Approach to Neuropathic Pain Management: A Systematic Review of Multi-Disciplinary Interventions.

*Ansari Aashif Raza Mohd Imtiyaz<sup>1</sup>, Dr. Deeparani Urolagin<sup>2</sup>*

<sup>1</sup>Research scholar, Department of Pharmacology, R R College of Pharmacy, Bangalore- India

<sup>2</sup>Professor & HOD, Department of Pharmacology, R R College of Pharmacy, Bangalore- India

Email: [ansariaashif251@gmail.com](mailto:ansariaashif251@gmail.com)

DOI: <https://doi.org/10.55248/gengpi.5.0524.1308>

### ABSTRACT

Neuropathic pain is a common symptom of a heterogeneous group of conditions, including diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, and spinal cord injury. Neuromodulation is presently prescribed as the fourth-line treatment of neuropathic torment after fizzled pharmacological treatment but sometimes recently low-dose opioids. This paper investigates the likenesses and contrasts between chronicled and current hones for the clinical administration of patients enduring neuropathic torment around the world, with a specific center on the US, Europe, and Japan.

**KEYWORDS:** Neuropathic pain, diabetic neuropathy, injury, treatment, clinical management.

### INTRODUCTION

Neuropathic torment, or torment related with infection or damage to the fringe or central anxious framework, [1] could be a common side effect of a heterogeneous gather of conditions, counting diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia and spinal line harm. [2] The genuine predominance of neuropathic torment is to a great extent obscure since of the need of legitimate epidemiologic considers. Current gauges propose that around 1.5% of the common populace within the US may be influenced, [3] and Bowsher has recommended that at slightest 1% of the UK populace endure from a few shape of neurogenic torment. [4] These figures are probably an belittle since there can be a neuropathic component within the torment experienced by patients with cancer, degenerative maladies, or neurologic conditions (such as Parkinson's infection) that has so distant gone unnoticed. These conditions are most predominant within the maturing populace; since the measure of this populace is increasing worldwide, neuropathic torment will definitely put a dynamically requesting burden on healthcare assets. Hence, there's a have to be reassess neuropathic torment and its treatment. This paper investigates the similitudes and contrasts between chronicled and current hones for the clinical administration of patients enduring from neuropathic torment around the world, with specific center on the US, Europe, and Japan.[5]

### Diagnosis

Whereas the history of torment investigate is long, dating back centuries, it was not until the Universal Affiliation for the Think about of Torment (IASP) was established in 1973 that consideration centered on the causes and treatment of neuropathic torment. The IASP distributed its to begin with list of torment terms in 1979. In any case, neuropathic torment was not included within the list until 1994, when it was at that point characterized as 'pain started or caused by a primary lesion or brokenness within the anxious system'. [6] This exceptionally wide definition typifies the concept that, when a nerve gets to be harmed, changes inside the neural pathways can result in incessant torment indeed within the nonappearance of a proceeding boost. In spite of the fact that this hypothesis has presently picked up common acknowledgment, it was at first a progressive thought that denied the Cartesian show of nociception and torment. In this way, neuropathic torment is categorically distinctive from nociceptive torment, which comes about from the enactment of nociceptive tactile axons by harmful boosts. Nociceptive torment is more often than not limited, localized, and dies down with mending or evacuation of the harmful substance. The characteristic side effects of neuropathic torment are depicted in more detail somewhere else in this supplement. The partition of boost from indication is somewhat mindful for the challenges in diagnosing neuropathic torment. In the event that the IASP definition is entirely connected, the clinician needs as it were to illustrate nerve harm or brokenness in a persistent encountering torment to form the conclusion of neuropathic torment. In any case, nerve harm and/or brokenness may show itself as negative side effects (tangible misfortune) as well as positive side effects (e.g., paresthesia, hyperalgesia). In spite of the fact that the affectability of the IASP definition is possibly tall, the specificity is moo, since not all patients with nerve damage involvement neuropathic torment. This may lead to a circumstance in which a persistent with nerve harm and coincidental torment from another source is misdiagnosed with neuropathic pain and along these lines abused. Alternately, neuropathic torment may be underdiagnosed when the signs and side effects of neural brokenness are not recognized. In this manner, the symptomatic work-up in patients with suspected neuropathic

torment must incorporate a point by point restorative history and audit of side effects, in expansion to a comprehensive physical and neurologic examination.[7] The restorative history gives knowledge into the onset, area, and conveyance of the torment (since this frequently matches the degree of the neural injury), and the conceivable affiliation of the torment with injury (e.g., surgery or current infections). In expansion, the quality of the torment ought to be recorded utilizing torment descriptors (e.g., shooting, burning, hurting) given by the understanding. Since the conclusion of neuropathic torment rests intensely on the show of tangible variations from the norm within the zone innervated by the suspected harmed nerve, a intensive clinical examination ought to be performed to decide the nearness and extent of tangible shortages, employing a run of rebellious (e.g., warm and cold metal rollers for temperature sensation, a camel hair brush for touch sensation, and a stick for torment sensation). A as of late presented appraisal tool—the Neuropathic Torment Scale (NPS)—has been developed based on descriptors that particularly characterize the foremost common qualities of neuropathic pain.[8] The NPS is an effortlessly managed apparatus that gives a reproducible examination of the sort of side effects experienced by the person quiet, which may inevitably permit the clinician to tailor treatment agreeing to the patient's indications. Whereas it remains to be decided whether the utilize of this scale contributes to changes within the conclusion or clinical administration of neuropathic torment, approval of national adaptations of this scale show up demonstrative of its potential clinical use.[9] Other scales particular to the appraisal of neuropathic torment are moreover beneath advancement (e.g., the Leeds Appraisal of Neuropathic Side effects and Signs Torment Scale). [10]

### Treatment Strategies

Truly, the most punctual treatment techniques for neuropathic torment were obtrusive in nature. By applying the Cartesian demonstrate for torment, it was trusted that blocking neural transmission, either incidentally utilizing neighborhood soporifics or forever by surgical nerve removal, would ease torment. These procedures were especially favored within the treatment of persistent torment related with removals or wounds endured by troopers amid the extraordinary War. In 1916, Leriche recommended that vasomotor changes seen in patients with fringe nerve harm might show an affiliation between torment and unusual vascular incitement:

this driven to the utilize of periarterial sympathectomy in an endeavour to lighten torment. Be that as it may, none of these treatments was found to be reliably fruitful. As of now, there are a few treatment procedures for overseeing neuropathic torment, counting both intrusive and non-invasive treatments. Distributed rules exist for the treatment of neuropathic torment in general,[11] as well as for the administration of neuropathic torment related with particular disorders, such as agonizing diabetic neuropathy [12,13] and trigeminal neuralgia. Be that as it may, these proposals are more often than not based on recounted prove or clinical trials appearing the adequacy of a treatment in a few patients with a specific causative condition for their neuropathic torment. In expansion, numerous of these early trials randomized little numbers of patients and were regularly ineffectively planned. [14 ]




Fig 1 : Algorithm for the treatment of neuropathic pain (GABA-B-gamma aminobutyric acid-B).

### Physiology and classification

The generation of pain in response to tissue injury involves four basic elements:

1. Transduction: a function of nociceptors that converts noxious stimulation to nociceptive signals

2. Transmission: a process that sends nociceptive signals along nerve fibres from the site of injury to the central nervous system (CNS)
3. Transformation or plasticity: a mechanism that modulates nociceptive signals at synaptic sites and at the level of the CNS through ascending, descending, or regional facilitation and inhibition
4. Perception: a key component of the clinical pain experience that integrates cognitive and affective (emotional) responses.

In developmental terms the enactment of high-threshold mechanical nociceptors or other sorts of specialized nociceptors served a defensive part, acting as a caution framework for perilous jolts. But while fiery torment is versatile, advancement has fizzled to account for our improved capacity to outlive injury, malady, or iatrogenic injury aiming to draw out or upgrade the quality of life (such as surgery). In these settings torment now not serves a valuable work but gets to be the illness itself. In spite of the fact that it is easy to conceptualize torment as a homogeneous substance, typically excessively simplistic. In reality there are a few diverse sorts, each with unmistakable neurobiological and pathophysiological components. The foremost common categorization partitions torment into two fundamental sorts:

neuropathic and nociceptive torment (table 1). This qualification is vital since it not as it were reflects the cause of torment but moreover illuminates treatment. Nociceptive torment can be classified as substantial (for case, muscles, joints) or less regularly visceral (inside organs). Since of the tall concentration of nociceptors in substantial tissues, persistent physical torment is regularly well localized and frequently comes about from degenerative forms (such as joint pain). By differentiate, inside organs are ordinarily inert to classic agonizing boosts, such as cutting and burning, but react to ischemia (for illustration, angina), irritation (a ruptured appendix), or impediment of stream that comes about in capsular distension (bowel obstacle). Neuropathic torment is characterized as torment coming about from damage to, or brokenness of, the somatosensory framework. In neuropathic torment, tissue harm straightforwardly influences the nervous framework, coming about within the era of ectopic releases that bypass transduction. One subtype of neuropathic torment is central pain (for illustration, as a result of spinal rope damage), which shows as a group of stars of signs and indications that takes after an insult to the CNS as a vital, but not continuously adequate, actuating occasion. In spite of the fact that numerous shapes of nociceptive pain, and a few shapes of neuropathic torment, may bestow developmental benefits, constant neuropathic torment is continuously maladaptive. Compared with past thinks about, gauges of the predominance of neuropathic torment have altogether expanded over the past decade since the advancement of rebellious planned to recognize such torment. Around 15-25% of individuals with incessant torment are right now thought to have neuropathic torment. In any case, the predominance of neuropathic torment may give a false representation of its financial affect, since considers have found that it is related with a more prominent negative affect on quality of life than nociceptive torment. [15,16,17,18]

Clinical characteristic	Neuropathic pain	Nociceptive pain
Cause	Injury to the nervous system, often accompanied by maladaptive changes in the nervous system	Damage or potential damage to tissues
Descriptors	Lancinating, shooting, electric-like, stabbing pain	Throbbing, aching, pressure-like pain
Sensory deficits	Common—for example, numbness, tingling, pricking	Uncommon; if present they have a non-dermatomal or non-nerve distribution
Motor deficits	Neurological shortcoming may be show in case a engine nerve is influenced; dystonia or spasticity may be related with central apprehensive framework injuries and in some cases fringe injuries (such as complex territorial torment disorder)	May have pain-induced weakness
Hypersensitivity	Pain often evoked by non-painful (allodynia) or painful (exaggerated response) stimuli	Uncommon except for hypersensitivity in the immediate area of an acute injury
Character	Distal radiation common	Distal radiation less common; proximal radiation more common
Paroxysms	Exacerbations common and unpredictable	Exacerbations less common and often associated with activity
Autonomic signs	Colour changes, temperature changes, swelling, or sudomotor (sweating) activity occur in a third to half of patients	Uncommon

**Table 1: Classification of neuropathic and nociceptive pain**

## TREATMENT OF NEUROPATHIC PAIN

### 1. Antiepileptic medications

#### a. Carbamazepine and oxcarbamazepine

The positive impacts of carbamazepine (an iminostilbene subsidiary) on trigeminal neuralgia were to begin with detailed in 1962 [19]. In spite of the fact that early trials don't meet advanced methodological measures (counting consider plan and need of suitable measurable examination), the pain relieving action of this sedate has been reported in a few difficult pathologies such as diabetic neuropathy, postherpetic neuralgia and tabetic torment [20]. Calculation of NNT in trigeminal neuralgia is 1.7 (1.3–2.2) and 2.3 (1.6–3.9) in postherpetic neuralgia. For agonizing diabetic neuropathy NNT is 3.3 (2–9.4). Doses run from 300 to 1000 mg/day, in separated dosages (twice a day). Side impacts (up to 70% of patients detailed passable unfavorable occasions) incorporate skin hasty (10% frequency), tipsiness, laziness, a negative impact on bone thickness, stride unsettling influence, hyponatraemia, seldom leukopenia and agranulocytosis. Carbamazepine moderates the recuperation rate of voltage-gated sodium channels in a frequency-dependent way. The medicate stifles dynamic torment filaments (A-Delta and C) without influencing normal nerve conduction. There's prove that carbamazepine produces a harmful epoxide metabolite:

standard bloods test are emphatically proposed in checking patients. Oxcarbamazepine (a component fundamentally related to carbamazepine) in dosages up to 1200 mg/day has appeared viability in one trial in diabetic neuropathic torment [21]. This medicate has a more generous profile and side impacts incorporate weariness, ataxia, sickness and cutaneous hasty (4%). Sodium blood observing is prompted (hyponatraemia develops in 2.5% of patients amid upkeep treatment) [22].

#### b. Lamotrigine

Lamotrigine could be a phenothiazine subordinate acting both on the blockage of voltage-dependent sodium channels (constricting terminating of activity possibilities) and on the restraint of B. Colombo et al.:

Drugs for neuropathic torment excitatory neurotransmitters glutamate and aspartate discharge. Positive impacts were detailed in randomized trials on neuropathic torment due to HIV disease (300 mg every day in a little consider) [23], spinal rope damage [24], central poststroke torment [25] (at a measurement of 200 mg/day in a randomized hybrid ponder, agonizing side effects were improved in 44% of patients), agonizing diabetic polyneuropathy (NNT=4) [26] and as an add-on treatment to headstrong patients (with phenytoin or carbamazepine) in trigeminal neuralgia (NNT=2.1) [27]. Skin hasty could be a not rare antagonistic impact of lamotrigine in both monotherapy and add-on trials, and is the foremost visit side impact driving to withdrawal. It is detailed [28] that an unfavorably susceptible skin response (a straightforward morbilliform hasty) can happen in 10% of treated patients, as a rule within the to begin with two months of treatment. More diffuse rashes happened in clinical trials in around one of 100 children and one of 300 grown-ups. The rate of detailed Stevens-Johnson disorder in clinical trials is one in 1000. Lamotrigine ought to be halted in patients who develop a hasty amid treatment, but this side impact can be diminished on the off chance that the sedate is begun at a really moo dose and gradually expanded each week (titrated to dosages between 200 and 400 mg/day). Other detailed side impacts were a sleeping disorder (more common), ataxia, sickness, obstruction, and diplopia. The utilize of lamotrigine with valproate ought to be maintained a strategic distance from since of the expanding frequency of Stevens-Johnson disorder (0.3% when utilized as an add-on treatment). Lamotrigine is right now proposed as a second-line sedate for neuropathic torment when first-line treatments are not viable.

#### c. Gabapentin

Despite the fact that this drug is a structural lipophilic analogue of GABA, it has no direct GABAergic activity. Pain relief should be mediated by interaction with alfa2-delta calcium channels [29] and direct or indirect inhibition of the release of excitatory amino acids. The drug is well adsorbed and does not bind to plasma proteins. Gabapentin has an FDA-approved indication for postherpetic neuralgia in the USA and is the most prescribed antiepileptic for the treatment of neuropathic pain in neurological practice. It has shown benefit in several randomised controlled trials including for postherpetic neuralgia [24, 25] and painful diabetic polyneuropathy [30, 31]. The starting dose was 900 mg/day up to the maximum tolerated dosage (3600 mg/day). The statistical efficacy in reducing pain if compared to placebo was  $p < 0.01$  for 1800 and 2400 mg doses and  $p < 0.001$  for 3600 mg dose. Improvements in quality of life, mood and sleep accompanied the amelioration in pain. Common well tolerated side effects include peripheral oedema (10%, especially in older patients at medium dosage), fatigue, dizziness and drowsiness. Some authors consider gabapentin as the first-line treatment for neuropathic pain with a 1–2-month titration plus 14 days at the higher tolerated dosage [32]. More studies are needed to evaluate whether the efficacy of gabapentin is maintained for more than 2 months. In the clinical management of neuropathic pain, a combination of gabapentin and morphine should be recommended when pain relief with gabapentin is incomplete. In a double-blind, randomised, crossover trial comparing monotherapy and combination therapy, treatment with morphine and gabapentin resulted in a greater reduction in pain at lower doses of each drug than did gabapentin alone, morphine alone or active placebo (low-dose lorazepam) in patients with either diabetic neuropathy or postherpetic neuralgia. Constipation, sedation and dry mouth were the most frequents side effects [33].

#### d. Pregabalin

Pregabalin was planned as a lipophilic GABA simple in 1990 and interatomic with the same authoritative location as its forerunner gabapentin. In December 2004 it was endorsed by the FDA for the treatment of neuropathic torment related with diabetic fringe neuropathy and postherpetic neuralgia. Like gabapentin, it isn't metabolized within the body, subsequently it isn't related with drug-drug intelligent and incorporates a way better toxicity-efficacy

proportion. Pregabalin has appeared its value in postherpetic neuralgia and diabetic polyneuropathy [34, 35] with a combined NNT for adaptable measurements extending from 150 to 600 mg and fixed-dose regimens of 3.8 (2.6–7.3). Significant diminishment of torment happens, on normal, inside 3 days of starting treatment. At the same time pregabalin was able to move forward rest, disposition unsettling influences and health-related quality of life in patients with postherpetic neuralgia. Detailed dose-related antagonistic impacts of pregabalin (gentle to direct) are discombobulation, lethargy, fringe oedema, weight pick up and dry mouth. Pregabalin clearance is diminished in subjects with impeded renal function, so a 50% decrease in day by day dosages is suggested for patients with renal brokenness. This specialist encompasses straight and dose-proportional assimilation inside the helpful measurements extend and a tall bioavailability (>90%). [36,37]

## 2. Antidepressant medications

Tricyclic antidepressants (TCA) were presented within the helpful armamentarium for agonizing diabetic neuropathy based on empiric perception approximately 30 a long time prior [38]. The adequacy of these drugs was afterward illustrated in a few controlled trials and is based on strong prove in a few neuropathic torment infections, i.e., amitriptyline for postherpetic neuralgia [39]. The pharmacological activities of antidepressants can be connected to balance of neuropathic torment, i.e., calcium channel blocking impact, sodium channel square, presynaptic reuptake restraint of serotonin and noradrenaline with upgrade of torment concealment through monoaminergic destinations, NMDA antagonist-like impact [40]. Unfavorable occasions of TCA incorporate tiredness, postural hypotension, anticholinergic impacts, QT interim anomalies and weight pick up. TCAs ought to be endorsed with caution in more seasoned patients or when a cardiac unsettling influence is suspected. The auxiliary amines nortriptyline and desipramine have a less genuine side-effects profile and have illustrated viability in patients with postherpetic neuralgia. Amitriptyline showed more viability within the alleviation of postherpetic neuralgia related torment than lorazepam [41], fluphenazine and maprotiline [42]. The proposed beginning dosage for amitriptyline is 10–25 mg/day, with a dosage increase of 10–25 mg each week up to an compelling measurements of 25–150 mg/day. A classical meta-analysis of antidepressants' adequacy in randomized placebo-controlled trials uncovered at slightest a 50% improvement of pain concentrated in 30% of patients influenced by neuropathic torment [43]. It is still questionable whether particular serotonin reuptake inhibitors (SSRI) and specific norepinephrine and serotonin reuptake inhibitors (SNRI) make strides neuropathic torment:

help in difficult diabetic neuropathy was accomplished with paroxetine and citalopram in two little trials in comparison with fake treatment [44, 45] while fluoxetine was not able to enhance excruciating side effects [46]. Side impacts of SSRI incorporate queasiness, heaving and dyspepsia. Venlafaxine restrains norepinephrine as well as serotonin reuptake at a dose >150 mg/day. There's eviS186 dence for a critical advancement in agonizing diabetic neuropathy [47] in a double-blind, placebo-controlled ponder with dosages between 150 and 225 mg/day (but not at a lower measurement) and a NNT around 4. Side impacts are comparable to SSRI. In agonizing diabetic neuropathy one can consider a combination treatment including venlafaxine to gabapentin on the off chance that the last mentioned given deficiently torment help [48]. Duloxetine, a auxiliary amine, was as of late endorsed (September 2004) by the FDA for the treatment of torment in diabetic fringe neuropathy at doses of 60 and 120 mg/day. A later think about illustrated that duloxetine was altogether way better than fake treatment with an NNT of 4.1 [49]. Enhancement ought to be determined in 7–14 days at 60 mg some time recently exchanging to the higher measurements. Visit side impacts of duloxetine incorporate languor, cerebral pain, dry mouth, weariness and queasiness (mellow to direct, regularly vanishes in two weeks). In case of sudden cessation, discombobulation and sickness are common. In outline, TCAs and SNRIs are successful in fringe neuropathic torment, to the same extend as other drugs such as gabapentin or opioids, while SSRIs have adequacy.

## 3. Opioids

Expanding information exist to back the common see that opioids and analgesics can be accommodating within the treatment of inveterate torment, keeping up an satisfactory side-effects profile. A few considers have given prove that tramadol (an atypical sedative pain relieving) may have a part within the treatment of excruciating diabetic fringe neuropathy [50–52] with an in general NNT of 3.9. Adequacy is more often than not accomplished at 250 mg/day, and a most extreme measurement of 400 mg is recommended. Tramadol moved forward torment concentrated, cruel day by day torment and side effects such as paraesthesia and touch-evoked torment. Tramadol is chemically diverse from the opioids but incorporates a coordinate powerless central opioid agonist impact with lowaffinity official to the mu-opiate receptor (though the major metabolite M1 features a more grounded opioid impact). Absence of pain initiated by tramadol is as it were somewhat offended by naloxone. At the same time, tramadol is able to hinder reuptake of both serotonin and norepinephrine. Side impacts incorporate queasiness, laziness and tipsiness. It is contraindicated on the off chance that the persistent incorporates a past history of seizures and medicate mishandle. Oxycodone has been effectively utilized in postherpetic neuralgia to altogether calm allodynia and paroxysmal torment [53] and in difficult diabetic neuropathy [54], with an NNT of 2.6, in spite of the fact that the ponders were as it were 2–3 months in length. Antagonistic occasions included stoppage, sedation, discombobulation, dry mouth, and queasiness. The medicate does not influence temperament and sadness. The cruel dose was 30–40 mg each 12 h (oxycodone controlled discharge). B. Colombo et al.:

Medicines for neuropathic pain The long-term utilize of opioids in neuropathic torment is still beneath wrangle about. [54]

## 4. Topical treatments

Lidocaine (5%) cured fix is demonstrated for alleviation of torment related with postherpetic neuralgia, but it is additionally suggested in rules for localized neuropathic torment. The prove for its pain-relieving impacts is restricted, but RCTs have found an impact with lidocaine fix in postherpetic neuralgia and localized neuropathic torment (Finnerup et al., 2010). In an open-label ponder, a comparable viability of topical lidocaine and pregabalin was proposed in patients with agonizing polyneuropathy and PHN (Aristocrat et al., 2009). Lidocaine fix ought to be connected as it were to intaglio skin. Side-effects are transitory and will usually resolve spontaneously inside a number of minutes to hours. They may comprise of rankles, skin disturbance, and a burning sensation at the location of application. Systemic antagonistic responses taking after fitting utilize of lidocaine patches are improbable, due to the little measurements retained.

Capsaicin is the substance regularly found in chili peppers and is an agonist of the transitory receptor potential vanilloid (TRPV1) receptor. Capsaicin hence Administration OF Agonizing NEUROPATHIES 285 fortifies the TRPV1 receptor on little afferent nociceptors whereby they ended up desensitized. High-dose (8%) capsaicin patches are affirmed by the European Drugs Office (EMA) for the treatment of fringe neuropathic torment in patients who don't have diabetes and by the Nourishment and Sedate Organization (FDA) for the treatment of postherpetic neuralgia. The capsaicin fix (NXG-4010 capsaicin) calmed HIV-related neuropathy with an NNT of 6.5 (3.9–19.7). Up to four patches can be utilized at the same time. After treating the skin range with a nearby anesthetic, the capsaicin fix remains connected for 30–60 minutes. The impact begins inside 1 day to 2 weeks after the application. The treatment may be rehashed each 3 months. Side-effects are as a rule transitory and self-limited and neighborhood with torment and redness at the location of application. As a result of treatment-related torment transitory increments in blood weight have been watched and blood weight ought to be observed amid treatment. Long-term viability and security with more than three applications have to be decided.

Botulinum poison sort A (BTX-A) has been appeared to have antinociceptive activities autonomous of the impact on muscle unwinding. One little RCT proposed impact of BTX-A in excruciating diabetic polyneuropathy (Yuan et al., 2009). BTX-A was infused intradermally within the excruciating zone and had a pain-relieving impact up to 12 weeks taking after infusion. Besides pain upon application, the treatment had no assist nearby or systemic side-effects. BTX-A treatment is expensive and more thinks about are required to affirm its long-term impact and value in neuropathy.

## 5. Recent advances in interventional management of neuropathic pain

### a. Infusion therapies

As portrayed over, mixture treatments are recommended within the treatment calculation for neuropathic torment. Whereas lidocaine and ketamine proceed to be ostensibly the two most common IV medicines utilized for neuropathic torment treatment, other drugs proceed to be examined as our understanding of neuropathic torment pathophysiology moves forward. Oxytocin, a neuropeptide created within the supraoptic and paraventricular cores of the hypothalamus, has appeared impacts in pre-synaptic hindrance of A $\delta$  and C-fiber signals at nociceptive-specific and wide energetic run neurons within the dorsal horn of the spinal rope [55]. This component of torment balance at the dorsal horn is thought to be a overwhelming theory for its administration of neuropathic torment, and is why ani- mal considers have looked for to approve the utilize of oxytocin for both nociceptive and neuropathic torment. An creature think about from 2005 evaluated electrical and mechanical torment resilience in 12 Sprague-Dawley rats with actuated neuropathic torment [56]. They connected changing measurements of oxytocin and found that oxytocin expanded torment resistance in neuropathic but not ordinary rats. In spite of the relatively robust discoveries from creature investigate with respects to IV oxytocin treatment, there's a scarcity of human subject inquire about on its impacts in persistent torment conditions, and particularly in neuropathic torment. In CRPS, IV bisphosphonates have been established as a potential treatment in hard-headed cases. A randomized, double-blind, placebo-controlled ponder comparing IV etidronate to fake treatment looked at 82 patients with CRPS sort 1 [57]. Patients were given 100 mg IV neridronate over 2 hours, for 4 medicines over 10 days. In the 40 days taking after implantation, the visual analog scale remained unaltered within the fake treatment group and advance diminished within the dynamic bunch by 46.5 mm (95% CI:–52.5, –40.5) vs. 22.6 mm (95% CI:–28.8, –16.3) for the fake treatment gather (P <0.0001) on a 100-point Visual Analogue Scale (VAS) scale. Their results were so encouraging that they concluded “bisphosphonates should be considered the first choice of treatment for CRPS type 1”. No serious side effects have been noted with IV bisphosphonate therapy in meta-analyses observing clinical efficacy [58].

### b. Neuroablative procedures

Neuroablative strategies like PRFA work by conveying electrical field and warm bursts to focused on nerves or tissues without forever dam- maturing these structures [59]. Novel approaches in how these electrical field and/or warm bursts are conveyed to nerves have looked for to diminish antagonistic impacts like tangible misfortune, dysesthesia, and bounce back neuralgia, whereas at the same time making strides life span of torment alleviation and indications. Later ponders have appeared the potential utility of low-temperature plasma radiofrequency removal (coblation) innovation as a treatment methodology for neuropathic torment [60]. This innovation utilizes radiofrequency vitality to energize the electrolytes that are show in a conductive medium such as saline, and subsequently shapes energized plasma. The release plasma at that point makes radical species that at that point connected with natural tissue and have adequate vitality to part atomic bonds, driving to tissue disintegration at moo temperatures of 40–70 °C. Coblation may suppress dorsal root ganglion (DRG) incitement, and in this manner decreases the incorrect ectopic input to the central apprehensive system—the potential component for neuropathic torment alleviation. Cryoneurolysis works by solidifying nerves, anticipating conduction of nerve driving forces to the tangible framework. In spite of being clinically in utilize since 1976, it has been underutilized as a methodology in neuropathic torment. Frameworks permitting ultrasound-guided cryoneurolysis have been as of late de- veloped to permit broader, more far reaching utilize of this methodology for hard-headed neuropathic torment. A later planned think about assessed 22 pa- tients with hard-headed fringe neuropathy who gotten percutaneous cryoablation, and torment scores were recorded at 1, 3, 6, 9 and 12 months post-procedure [61]. Cruel torment levels on a 10-point visual analog scale were 8.3±1.9 some time recently mediation and 2.3±2.5 at 1 month, 3.2±2.5 at 3 months, 4.7±2.7 at 6 months, and 5.1±3.7 at 12 months a while later. These were factually critical diminishes between pre- and post-procedural torment scores. There were no complications detailed from the strategies.

### c. Neuromodulation

Since Dr. Shealy to begin with spearheaded neuromodulation by means of SCS as an implantable treatment in 1967, its clinical adequacy and victory in treating neuropathic torment has progressed significantly [62]. Neuromodulation is presently suggested as the fourth line treatment of neuropathic torment after fizzled pharmacological treatment but some time recently moo measurements opioids Administration of neuropathic torment is the foremost common reason for utilizing neuromodulation. As a treatment, this will be encourage broken down into SCS, DRG incitement and fringe nerve incitement (PNS). In expansion, with the change in innovation and expanding understanding of neuromodulation, diverse modes of incitement have assist progressed its viability and signs for treatment. The Neuromodulation Fittingness Agreement Committee (NACC) of the Worldwide Neuromodulation Society (INS)

distributed agreement papers for SCS in 2014 and for DRG incitement in 2018, with a audit of the prove to date and suggestions of when each treatment is fitting [63,64]. A later precise audit illustrated that SCS leads to a diminish in torment escalated when compared with fake treatment treatment [65]. Signs for neuromodulation have extended to incorporate pivotal back torment, fringe neuropathy (counting human immunodeficiency infection neuropathy) and diabetic neuropathy, abdominal/pelvic torment, postamputation torment, and postsurgical torment disorders counting post-thoraco-tomy, post-inguinal hernia repair, and post knee surgery torment . The component for neuromodulation's helpful reaction isn't completely caught on but it shows up to be related with fringe (distal to the DRG), spinal cord/segmental (DRG and spinal line) and supraspinal impacts depending upon the condition, the area of incitement, and the mode of incitement [66]. Conventional tonic incitement (40–100 Hz) impacts were initially clarified by the Gate Control Hypothesis where actuation of the large-diameter afferents (A-beta filaments) brought about in restraint of little (A $\delta$  and C) strands [67]. In any case, all the impacts of SCS seem not be clarified by this hypothesis. Investigate has appeared that neuromodulation comes about in nearby changes of wide energetic neuron volatility, help of physiologic hindrance components, and changes in enactment of neurotransmitters counting gamma aminobutyric corrosive (GABA), glutamate, adenosine, acetylcholine, substance P, calcitonin gene-related peptide (CGRP), brain-derived neurotrophic figure (BDNF), and bradykinins. Supraspinal instruments for the impacts of SCS have too been appeared to modify electroencephalogram possibilities and cerebral blood stream in utilitarian attractive reverberation imaging (fMRI) considers [68,69]. With the headway of innovation, unused leads and modes of incitement past tonic incitement have encourage progressed the viability of neu- romodulation in neuropathic torment. DRG incitement has permitted for more centered treatment and progressed results in conditions that were challenging to treat. Beginning studies with DRG incitement and lower appendage CRPS recommended moved forward torment diminishment and vasomotor changes [70]. Advance discrete zones of torment are more effortlessly focused on with DRG incitement such as post inguinal hernia surgery torment. High-Frequency stimu- lation (10 kHz) has appeared to be compelling in calming torment, diminishing inability, and making strides quality of life, particularly in patients with pivotal moo back and leg torment [71]. Differential target multiplexed (DTM) incitement is another mode of incitement that shows up promising within the treat- ment of moo back torment [72]. DTM employments different electrical signals shifting in recurrence, beat width and sufficiency. Bigger randomized considers are required to decide its viability. Non-linear burst incitement utilizes 40 Hz bursts with five spikes at 500 Hz per burst at a rate of 40 bursts per moment to modulate neuronal action within the average and sidelong pathways of the brain (thought to conduct affective components of torment), and has been appeared to supply superior torment help than customary tonic incitement [73,74].Neuromodulation is presently on the cutting edge of treatment as pharmacological mediations have more than once fizzled with noteworthy side impacts and dangers of habit. It shows up at that point that neuromodulation may be long haul of neuropathic torment administration. Multicenter, randomized con- trolled trials, and investigate of instruments must be encourage done to illustrate its helpful signs and cost-effectiveness.[75]

---

## CONCLUSION

In conclusion, the management of neuropathic pain presents a complex interplay of historical and current practices, diagnosis, treatment strategies, physiological understanding, and recent advances in interventional management. The diagnosis process involves a comprehensive medical history, review of symptoms, and a detailed physical and neurological examination, complemented by the use of specific assessment tools. Treatment strategies, both historical and current, range from invasive interventions to non-invasive pharmacological approaches, each with their unique benefits and concerns. Pharmacological treatment options have expanded to include antiepileptic medications, antidepressants, opioids, and topical treatments, with recent advances in interventional management showing promise in delivering effective relief. These include infusion therapies, neuroablative procedures, and neuromodulation, each offering new avenues for addressing neuropathic pain.\n\nThe classification of pain—particularly distinguishing between neuropathic and nociceptive pain—allows for a more tailored approach to treatment. The development and use of specific medications, such as antiepileptic drugs, antidepressants, and opioids, have shown positive outcomes in the management of neuropathic pain, with a focus on addressing specific symptoms and improving quality of life. Recent advances in interventional approaches, including infusion therapies, neuroablative procedures, and neuromodulation, offer additional tools in the treatment arsenal, paving the way for more targeted and effective strategies, the shifting landscape of neuropathic pain management underscores the importance of tailored approaches, continuous research, and the exploration of innovative interventions. By fostering multidisciplinary collaboration and embracing evolving techniques, the field of neuropathic pain management continues to advance, aiming to improve patient outcomes and overall quality of life. Further research and clinical studies are needed to refine and expand these approaches, ultimately enhancing the comprehensive care and treatment of individuals experiencing neuropathic pain.

---

## REFERENCES

1. Merskey H, Bogduk N, eds. Classification of chronic pain (2nd edition). Seattle: IASP Press, 1994.
2. Jensen TS, Gottrup H, Sindrup SH, et al. The clinical picture of neuropathic pain. *Eur J Pharma col* 2001; 429:1–11.
3. Carter GT, Galer BS. Advances in the management of neuropathic pain. *Phys Med Rehabil Clin N Am* 2001; 12:447–459.
4. Bowsher D. Neurogenic pain syndromes and their management. *Br Med Bull* 1991; 47:644–666.
5. Smith TE, Chong MS. Neuropathic pain. *Hosp Med* 2000; 61:760–766.
6. IASP (International Association for the Study of Pain). IASP Pain Terminology. <http://www.halcyon.com/iasp/terms-p.html>.
7. Hansson P. Neuropathic pain: clinical characteristics and diagnostic workup. *Eur J Pain* 2002; 6:47–50.

8. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. *Neurology* 1997; 48:332–338.
9. Negri E, Bettaglio R, Demartini L, et al. Validation of the Italian version of the “neuropathic pain scale” and its clinical implications. *Minerva Anesthesiol* 2002; 68:95–104.
10. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. *Pain* 2001; 92:147–157.
11. Orza F, Boswell MV, Rosenberg SK. Neuropathic pain: Review of mechanisms and pharmacologic management. *Neurorehabilitation* 2000; 14:15–23.
12. Boulton AJM, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. *Diabet Med* 1998;15: 508–514.
13. Page JC, Chen EY. Management of painful diabetic neuropathy. A treatment algorithm. *J Am Podiatr Med Assoc* 1997; 87:370–379.
14. Perkin GD. Trigeminal neuralgia. *Curr Treat Options Neurol* 1999; 1:458–465.
15. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. *Neurology* 2008; 70:1630-5.
16. Devor M. Neuropathic pain and injured nerve: peripheral mechanisms, *Br Med Bull* 1991;47:619-30.
17. Freynhagen R, Baron R, Gockel U, Tolle TR. Pain DETECT a new screening questionnaire to identify neuropathic components in patients with back pain. *Curr Med Res Opin* 2006; 22:1911-20.
18. Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. *Clin J Pain* 2007; 23:143-9.
19. Blom S (1962) Trigeminal neuralgia: its treatment with a new anticonvulsant drug. *Lancet* 1:839–840
20. Backonja MM (2002) Use of anticonvulsant for treatment of neuropathic pain. *Neurology* 59:S14–S17
21. Beydoun A, Kobetz SA, Carrazana EJ (2004) Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. *Clin J Pain* 20:174–178
22. Trileptal [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ B. Colombo et al.: Medications for neuropathic pain S187
23. Simpson DM, Olney R, McArthur KC, Khan A, Godbold J, Ebel-Frommer K (2000) A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. *Neurology* 54:2115–2119
24. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS (2002) Lamotrigine in spinal cord injury pain: a randomized controlled trial. *Pain* 96:375–383
25. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS (2001) Lamotrigine for central poststroke pain: a randomized controlled trial. *Neurology* 56:184–190
26. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A (2001) Lamotrigine reduces painful diabetic neuropathy: a randomized controlled study. *Neurology* 57:505–509
27. Zakrewska JM, Claudhry Z, Nurmikko TJ et al (1997) Lamotrigine in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. *Pain* 73:223–230
28. Guberman AH, Besag FM, Brodie MJ et al (1999) Lamotrigine associated rash: risk/benefit consideration in adults and children. *Epilepsia* 40:985–991
29. Taylor CP, Gee NS, Su TZ et al (1998) A summary of mechanistic hypothesis of gabapentin pharmacology. *Epilepsy Res* 29:233–249
30. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus Miller L (1998) Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. *JAMA* 280:1837–1842
31. Rice AS, Maton S, and the Postherpetic Neuralgia Study Group (2001) Gabapentin in Postherpetic Neuralgia a randomized double-blind, placebo controlled study. *Pain* 94:215–224
32. Backonja M, Beydoun A, Edwards KR et al (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. *JAMA* 280:1831–1836
33. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM (1999) Gabapentin in the treatment of painful diabetic neuropathy: a placebo-controlled double-blind, crossover trial. *J Neurol Neurosurg Psychiatry* 66:251–252



34. Dworkin RH, Backonja M, Rowbotham MC et al (2003) Advances in neuropathic pain: diagnosis, mechanisms and treatment recommendations. *Arch Neurol* 60:1524–1534
35. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL (2005) Morphine, gabapentin or their combination for neuropathic pain. *N Engl J Med* 352:1324–1334
36. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo controlled trial. *Pain* 110:628–638
37. Freynhagen R, Stojek K, Griesing T, Whalen E, Balkenohl M (2005) Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. *Pain* 115:254–263
38. Davis JL, Lewis SB, Gerich JE, Kaplan RA, TA Schultz, Wallin JD (1977) Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. *J Am Med Assoc* 238:2291–2292
39. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J (1982) Amitriptyline versus placebo in postherpetic neuralgia. *Neurology* 32:671–673
40. Sindrup SH, Otto M, Finnerup NB, Jensen TS (2005) Antidepressants in the treatment of neuropathic pain. *Basic Clin Pharmacol Toxicol* 96:399–409
41. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH (1988) Amitriptyline but not lorazepam relieves postherpetic neuralgia. *Neurology* 38:1427–1432
42. Graff-Radford SB, Shaw LR, Naliboff BN (2000) Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. *Clin J Pain* 16:188–192
43. Watson CPN, Chipman M, Reed K, Evans RJ, Bikett N (1992) Amitriptyline versus maprotiline in postherpetic neuralgia: a randomised double-blind, crossover trial. *Pain* 48:29–36
44. Sindrup SH, Jensen TS (2000) Pharmacologic treatment of pain in polyneuropathy. *Neurology* 55:915–920
45. Sindrup SH, Gram LF, Brosen K, Eshoj O, Morgensen EF (1990) The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. *Pain* 42:135–144
46. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aes-Jorgensen T, Gram LF (1992) The serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. *Clin Pharmacol Ther* 52:547–552
47. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R (1992) Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. *N Engl J Med* 326:1250–1256
48. Rowbotham MC, Goli V, Kunz NR, Lei D (2004) Venlafaxine extended release in the treatment of painful diabetic polyneuropathy: a double-blind placebo-controlled study. *Pain* 110:697–706
49. Simpson DA (2001) Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. *J Clin Neuromusc Dis* 3:53–62
50. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S (2005) Duloxetine versus placebo in patients with painful diabetic neuropathy. *Pain* 116:109–118
51. Harati Y, Gooch C, Swenson M et al (1998) Double-blind randomised trial of tramadol for the treatment of the pain of diabetic neuropathy. *Neurology* 50:1842–1846
52. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS (1999) Tramadol relieves pain and allodynia in polyneuropathy: a randomised double-blind controlled trial. *Pain* 83:85–90
53. Boureau F, Legalicier P, Kabir-Ahmadi M (2003) Tramadol in post-herpetic neuralgia: a randomised, double-blind, placebo-controlled trial. *Pain* 104:323–331.
54. Watson CPN, Babul N (1998) Efficacy of oxycodone in neuropathic pain: a randomised trial in postherpetic neuralgia. *Neurology* 50:1837–1841
55. Rash JA, Aguirre-Camacho A, Campbell TS. Oxytocin and Pain: A Systematic Review and Synthesis of Findings. *Clin J Pain* 2014;30:453-62.
56. Condés-Lara M, Maie I, Dickenson A. Oxytocin actions on afferent evoked spinal cord neuronal activities in neuropathic but not in normal rats. *Brain Res* 2005;1045:124-33. [10.1016/j.brainres.2005.03.020](https://doi.org/10.1016/j.brainres.2005.03.020).
57. Varenna M, Adami S, Rossini M, et al. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. *Rheumatology* 2013;52:534-42. [10.1093/rheumatology/kes312](https://doi.org/10.1093/rheumatology/kes312)

58. Chevreau M, Romand X, Gaudin P, et al. Bisphosphonates for treatment of Complex Regional Pain Syndrome type 1: A systematic literature review and meta-analysis of randomized controlled trials versus placebo. *Joint Bone Spine* 2017;84:393-9. 10.1016/j.jbspin.2017.03.009
59. Chang MC. Efficacy of Pulsed Radiofrequency Stimulation in Patients with Peripheral Neuropathic Pain: A Narrative Review. *Pain Physician* 2018;21:E225-34. 10.36076/ppj.2018.3.E225
60. Li H, Li Y, Guo Z, et al. Low-temperature plasma radiofrequency ablation in phantom limb pain: A case report. *Brain Circ* 2018;4:62-4. 10.4103/bc.bc\_7\_17
61. Yoon JHE, Grechushkin V, Chaudhry A, et al. Cryoneurolysis in Patients with Refractory Chronic Peripheral Neuropathic Pain. *J Vasc Interv Radiol* 2016;27:239-43. 10.1016/j.jvir.2015.11.027
62. Shealy CN, Mortimer JT, Reswick JB. Electrical inhibition of pain by stimulation of the dorsal columns: preliminary clinical report. *Anesth Analg* 1967;46:489-91. 10.1213/0000539-196707000-00025
63. Deer TR, Mekhail N, Provenzano D, et al. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: The neuromodulation appropriateness consensus committee. *Neuromodulation* 2014;17:515-50. 10.1111/ner.12208
64. Deer TR, Pope JE, Lamer TJ, et al. The Neuromodulation Appropriateness Consensus Committee on Best Practices for Dorsal Root Ganglion Stimulation. *Neuromodulation* 2019;22:1-35. 10.1111/ner.12845.
65. Duarte R V., Nevitt S, McNicol E, et al. Systematic review and meta-analysis of placebo/sham controlled randomised trials of spinal cord stimulation for neuropathic pain. *Pain* 2020;161:24-35. 10.1097/j.pain.0000000000001689.
66. Jensen MP, Brownstone RM. Mechanisms of spinal cord stimulation for the treatment of pain: Still in the dark after 50 years. *Eur J Pain* 2019;23:652-9. 10.1002/ejp.1336.
67. Sdrulla AD, Guan Y, Raja SN. Spinal Cord Stimulation: Clinical Efficacy and Potential Mechanisms. *Pain Pract* 2018;18:1048-67. 10.1111/papr.12692 .
68. Bocci T, De Carolis G, Paroli M, et al. Neurophysiological Comparison Among Tonic, High Frequency, and Burst Spinal Cord Stimulation: Novel Insights Into Spinal and Brain Mechanisms of Action. *Neuromodulation* 2018;21:480-8. 10.1111/ner.12747.
69. A, Kozák J, Vrba I, et al. Functional magnetic resonance imaging of cerebral activation during spinal cord stimulation in failed back surgery syndrome patients. *Eur J Pain* 2008;12:137-48. 10.1016/j.ejpain.2007.03.003 .
70. Deer TR, Levy RM, Kramer J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: A randomized comparative trial. *Pain* 2017;158:669-81. 10.1097/j.pain.0000000000000814.
71. Kapural L, Yu C, Doust MW, et al. Novel 10-kHz High-frequency Therapy (HF10 Therapy) Is Superior to Traditional Low-frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain. *Anesthesiology* 2015;123:851-60. 10.1097/ALN.0000000000000774.
72. Fishman MA, Calodney A, Kim P, et al. Prospective, Multicenter Feasibility Study to Evaluate Differential Target Multiplexed Spinal Cord Stimulation Programming in Subjects With Chronic Intractable Back Pain With or Without Leg Pain. *Pain Pract* 2020;20:761-8. 10.1111/papr.12908.
73. Chakravarthy K, Fishman MA, Zuidema X, et al. Mechanism of Action in Burst Spinal Cord Stimulation: Review and Recent Advances. *Pain Med* 2019;20:S13-22. 10.1093/pm/pnz073.
74. Chakravarthy K, Kent AR, Raza A, et al. Burst Spinal Cord Stimulation: Review of Preclinical Studies and Comments on Clinical Outcomes. *Neuromodulation* 2018;21:431-9. 10.1111/ner.12756.
75. Chakravarthy K, Malayil R, Kirketeig T, et al. Burst Spinal Cord Stimulation: A Systematic Review and Pooled Analysis of Real-world Evidence and Outcomes Data. *Pain Med* 2019;20:S47-57. 10.1093/pm/pnz046.